New combo therapy aims to personalize lung cancer treatment
NCT ID NCT07624487
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is for people with a specific type of advanced lung cancer (EGFR L858R mutation). It tests a treatment plan that starts with a targeted drug (aumolertinib) alone for 6 weeks, then adds chemotherapy for 4 cycles, and finally continues with the targeted drug alone. The goal is to see if early changes in tumor DNA in the blood can predict who benefits most, potentially allowing some patients to avoid chemotherapy in the future. About 50 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aumolertinib combined with pemetrexed and carboplatin chemotherapy
- What this could lead to
- If successful, this could lead to a more personalized treatment approach for EGFR L858R lung cancer, potentially sparing some patients from unnecessary chemotherapy while improving outcomes for others.
- What could go wrong
- This is a small, early-phase (Phase 2) trial with only 50 participants, so results may not apply to everyone. Combining chemotherapy with a targeted drug also increases the risk of side effects like fatigue, nausea, and low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR L858R-MUTATED METASTATIC LUNG ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shuang Ho Hospital
NOT_YET_RECRUITINGNew Taipei City, Taiwan
-
Taipei Medical University Hospital
RECRUITINGTaipei, Taiwan
-
Wanfang Hospital
NOT_YET_RECRUITINGTaipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.